# TG Therapeutics Inc. (TGTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $55.98, market value $8.6 billion.

## Valuation
- **P/E (trailing): 20.4×** (5-yr avg 133.7×, 3-yr avg 133.7×). TG Therapeutics Inc. trades at 20.4× trailing earnings, well below its own five-year average of 133.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.01**. A PEG of 0.01 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 10.7×**. Each dollar of revenue is priced at 10.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 13.6×**. The shares trade at 13.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 64.0×**. Enterprise value is 64.0× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 0.2%** (5-yr avg -5.1%). Free cash flow equals 0.2% of the market value, above its five-year average of -5.1%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 4.9%**. The inverse of the P/E: 4.9% of the price is earned each year.

## Profitability
- **Operating margin: 17.1%**. 17.1% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 72.6%**. 72.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 69.0%**. A 69.0% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 13.2%**. Return on all capital, debt included, is 13.2%.
- **Return on assets: 41.5%**. Each dollar of assets produces 41.5% of profit.

## Growth
- **Revenue growth (1 yr): 87.3%** (3-yr 504.9%/yr, 5-yr 426.7%/yr). Revenue grew 87.3% over the last year, against 426.7% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 1746.7%**. Earnings per share rose 1746.7%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.38**. Debt is 0.38 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.2×**. It would take 1.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 14.20**. A Z-score of 14.20 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. TG Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover TG Therapeutics Inc.; the consensus is strong_buy, with an average price target of $69.71 (+25% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 75.6%** (YTD 87.8%, 3-mo 39.4%). The shares are up 75.6% over twelve months including dividends.
- **From 52-week high: -5.6%** (109.2% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 0.59** (volatility 45%). Beta of 0.59 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TGTX · Page: https://foliofundamentals.com/stocks/tgtx

Not investment advice.